ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary

With honor comes scrutiny. Ivonescimab's plenary status means its Harmoni-6 results in first-line non-small cell lung cancer will be put under the microscope and critiqued carefully at the upcoming ASCO 2026 annual meeting.